| 1.285 0.065 (5.33%) | 05-16 13:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.55 |
1-year : | 1.74 |
| Resists | First : | 1.33 |
Second : | 1.49 |
| Pivot price | 1.29  |
|||
| Supports | First : | 1.08 |
Second : | 0.89 |
| MAs | MA(5) : | 1.22 |
MA(20) : | 1.27 |
| MA(100) : | 1.89 |
MA(250) : | 1.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.6 |
D(3) : | 19.9 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 5.17 | Low : | 0.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACRS ] has closed above bottom band by 39.7%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.24 - 1.25 | 1.25 - 1.26 |
| Low: | 1.14 - 1.15 | 1.15 - 1.16 |
| Close: | 1.2 - 1.22 | 1.22 - 1.24 |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Wed, 14 May 2025
Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus
Mon, 12 May 2025
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN
Sat, 10 May 2025
Aclaris Therapeutics Reports Q1 2025 Financial Results - TipRanks
Fri, 09 May 2025
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire
Thu, 08 May 2025
Aclaris: Q1 Earnings Snapshot - CTPost
Thu, 08 May 2025
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 108 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 86.1 (%) |
| Shares Short | 4,070 (K) |
| Shares Short P.Month | 6,030 (K) |
| EPS | -1.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | 0 % |
| Operating Margin | -152.8 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -84.5 % |
| Qtrly Rev. Growth | -47.6 % |
| Gross Profit (p.s.) | -0.29 |
| Sales Per Share | 0.17 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.74 |
| PEG Ratio | 0 |
| Price to Book value | 0.87 |
| Price to Sales | 7.31 |
| Price to Cash Flow | -6.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|